DDIT3 and diffuse large B-cell lymphoma: Although the addition of rituximab to CHOP (R-CHOP) increased the CR rate, PFS, and OS in DLBCL [38,39], especially in younger patients with low clinical risk, a recent study reported that there was no statistical difference in PPL-DLBCL following a retrospective comparison of patients who received R-CHOP or CHOP alone [40].